Epidemiology of systemic sclerosis in Quebec, Canada: a population-based study.

Epidemiology Incidence Mortality Populational Prevalence Systemic sclerosis

Journal

Lancet regional health. Americas
ISSN: 2667-193X
Titre abrégé: Lancet Reg Health Am
Pays: England
ID NLM: 9918232503006676

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 08 11 2023
revised: 18 04 2024
accepted: 14 05 2024
medline: 4 7 2024
pubmed: 4 7 2024
entrez: 4 7 2024
Statut: epublish

Résumé

Systemic sclerosis (SSc) is a systemic life-threatening autoimmune rheumatic disease. We aimed to assess the incidence, prevalence, mortality and spatiotemporal trends of SSc in Quebec, Canada with stratification by sex and age. SSc cases were identified from Quebec populational databases from 1989 to 2019. Negative Binomial (NB) Generalized Linear Models were used for age-standardized incidence rates (ASIR) analyses and NB random walk for prevalence and mortality. A Poisson Besag-York-Mollié regression model was used for spatial analysis. 8180 incident SSc cases were identified between 1996 and 2019 with an average age of 57.3 ± 16.3 years. The overall ASIR was 4.14/100,000 person-years (95%, Confidence Interval (CI) 4.05-4.24) with a 4:1 female predominance. ASIR increased steadily over time with an Average Annual Percent Change (AAPC) of 3.94% (95% CI 3.49-4.38). While the highest incidence rates were in those aged 60-79 years old among females and >80 years old among males, the highest AAPC (∼10%) was seen in children. Standarized incidence ratios varied geographically between 0.52 to 1.64. The average prevalence was 28.96/100,000 persons (95% CI 28.72-29.20). The Standardized Mortality Ratio (SMR) decreased from 4.18 (95% CI 3.64-4.76) in 1996 to 2.69 (95% CI 2.42-2.98) in 2019. Females had a greater SMR until 2007 and males thereafter. The highest SMR was in children and young adults [31.2 (95% CI 8.39-79.82) in the 0-19-year age group]. We showed an increasing trend in SSc incidence and prevalence and a decline in SMR over a 25-year period in Quebec. An uneven geographic distribution of SSc incidence was demonstrated. National Scleroderma Foundation, Canadian Dermatology Foundation/Canadian Institutes of Health Research.

Sections du résumé

Background UNASSIGNED
Systemic sclerosis (SSc) is a systemic life-threatening autoimmune rheumatic disease. We aimed to assess the incidence, prevalence, mortality and spatiotemporal trends of SSc in Quebec, Canada with stratification by sex and age.
Methods UNASSIGNED
SSc cases were identified from Quebec populational databases from 1989 to 2019. Negative Binomial (NB) Generalized Linear Models were used for age-standardized incidence rates (ASIR) analyses and NB random walk for prevalence and mortality. A Poisson Besag-York-Mollié regression model was used for spatial analysis.
Findings UNASSIGNED
8180 incident SSc cases were identified between 1996 and 2019 with an average age of 57.3 ± 16.3 years. The overall ASIR was 4.14/100,000 person-years (95%, Confidence Interval (CI) 4.05-4.24) with a 4:1 female predominance. ASIR increased steadily over time with an Average Annual Percent Change (AAPC) of 3.94% (95% CI 3.49-4.38). While the highest incidence rates were in those aged 60-79 years old among females and >80 years old among males, the highest AAPC (∼10%) was seen in children. Standarized incidence ratios varied geographically between 0.52 to 1.64. The average prevalence was 28.96/100,000 persons (95% CI 28.72-29.20). The Standardized Mortality Ratio (SMR) decreased from 4.18 (95% CI 3.64-4.76) in 1996 to 2.69 (95% CI 2.42-2.98) in 2019. Females had a greater SMR until 2007 and males thereafter. The highest SMR was in children and young adults [31.2 (95% CI 8.39-79.82) in the 0-19-year age group].
Interpretation UNASSIGNED
We showed an increasing trend in SSc incidence and prevalence and a decline in SMR over a 25-year period in Quebec. An uneven geographic distribution of SSc incidence was demonstrated.
Funding UNASSIGNED
National Scleroderma Foundation, Canadian Dermatology Foundation/Canadian Institutes of Health Research.

Identifiants

pubmed: 38962065
doi: 10.1016/j.lana.2024.100790
pii: S2667-193X(24)00117-0
pmc: PMC11220520
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100790

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors have no declaration of interest to disclose.

Auteurs

Anastasiya Muntyanu (A)

Division of Experimental Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
Division of Dermatology, University of Toronto, Toronto, Ontario, Canada.

Katherine Aw (K)

Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Mohammed Kaouache (M)

The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.

Elham Rahme (E)

Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Division of Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.

Mohamed Osman (M)

Division of Rheumatology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Murray Baron (M)

Division of Rheumatology, Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada.

Stephanie Ghazal (S)

Division of Dermatology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.

Elena Netchiporouk (E)

Division of Dermatology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.

Classifications MeSH